FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response	e· 0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Arbuckle Stuart A</u>					2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]								k all app Direc	ionship of Reporting all applicable) Director		rson(s) to Is			
(Last)	(Fir	st) (N	/liddle)		3. Date of Earliest Transaction (Month/Day/Year) 12/29/2023							Office	er (give title		Other (s below)	specify			
C/O IMMUNOGEN, INC. 830 WINTER STREET				4. If <i>F</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicatione) X Form filed by One Reporting Person					·			
(Street)	AM M	A 0.	2451												Form Perso	filed by Mo	re thai	n One Repo	orting
(City)	(Sta	ate) (Z	(ip)		$ _{\Box}$	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								nded to					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day			Execution Dat		ate,	Transaction D Code (Instr. 5		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)				Securit Benefic Owned			n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) c	Pric	е	Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common Stock 12/29/2			12/29/2	2023		A		442	A (1	1) \$29	9.65	5 5,381			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any			saction e (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		nt		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)					
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	of Shares						

Explanation of Responses:

1. Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 in lieu of cash compensation for services performed for the quarter ended December 31, 2023.

/s/ Renee Lentini, Attorney-in-01/03/2024

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.